Related Articles Premium How Electron Is Rewiring Its Portfolio This Year After a Muted Finish to 2025 Stephen Taub Premium From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory Stephen Taub 6 for 2026: Essential Questions for Investors Sponsored by BNY Investments